SuperworthPerspective Therapeutics market cap CATX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $183.8M
- Highest close in our data
- $1.1B
- Aug 2024
Perspective Therapeutics is worth $183.8M at the close on Oct 23, 2026, at $1.61 a share.
That is down 17% over the last year and up 114% over five years.
Its highest close in our data was $1.1B in Aug 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $183.8M | $173.2M | $513.8M | −14% |
| 2025 | $214.1M | $133.3M | $360.9M | −1% |
| 2024 | $215.6M | $133.8M | $1.1B | +91% |
| 2023 | $112.8M | $37.8M | $199.5M | +221% |
| 2022 | $35.1M | $32.7M | $59.7M | −36% |
| 2021 | $55.1M | $55.1M | $234.4M | +40% |
| 2020 | $39.3M | $25.3M | $62.2M | −5% |
| 2019 | $41.2M | $20.7M | $44.5M | +91% |
| 2018 | $21.5M | $20.9M | $34.9M | −2% |
| 2017 | $22M | $22M | $37.9M | −31% |
| 2016 | $31.9M | $30.3M | $63.3M | −38% |
| 2015 | $51.6M | $51.6M | $101M | −39% |
| 2014 | $84M | $19.4M | $173M | +341% |
| 2013 | $19M | $16.6M | $28.4M | −27% |
| 2012 | $25.9M | $11.4M | $43.1M | +36% |
| 2011 | $19.1M | $19.1M | $20.3M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Perspective Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| CATXPerspective Therapeutics | $183.8M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| ARVNArvinas | $477.3M |
| SPROSpero Therapeutics | $64.6M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| ATNMActinium Pharmaceuticals | $47.8M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Perspective Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.